Effects of Individualized iTBS on Upper Limb Function After Stroke
Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Nov 19, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called individualized intermittent theta burst stimulation (iTBS) to see if it can improve upper limb function in people who have had a stroke. The goal is to find out if this personalized approach is better than the standard iTBS treatment. The researchers want to know not only if the treatment helps patients move their arms and hands better but also if these improvements last over time. They will use a special technique called functional near-infrared spectroscopy (fNIRS) to understand how the treatment works in the brain.
To be eligible for the trial, participants must be aged 18 to 80, have had their first stroke within the last 1 to 3 months, and experience some difficulty using their arms. They also need to be able to understand the study and agree to participate by signing a consent form. Participants will go through some tests before starting the treatment and will be randomly assigned to one of three groups: one receiving individualized iTBS, another getting standard iTBS, and a third group receiving a placebo treatment that doesn’t have any active ingredients. Throughout the study, participants will have follow-up assessments to monitor their progress. This trial is not yet recruiting participants, but it aims to provide valuable information on how best to help stroke survivors regain upper limb function.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. aging from 18-80
- • 2. diagnosed as first-happened stroke,duration of the disease ranged from 1-3 months
- • 3. upper extremity impairment
- • 4. with mini-mental state examination\>15
- • 5. agree to participate in this study and sigh the informed consent
- Exclusion Criteria:
- • 1. with stroke history
- • 2. have metal device within the body
- • 3. with history of upper extremity trauma,fracture, and/or burn
- • 4. serious conditions and can not finish the examination and treatment
About Qilu Hospital Of Shandong University
Qilu Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Affiliated with Shandong University, the hospital integrates clinical practice with education and research, fostering an environment that promotes scientific discovery and the development of new therapies. With a commitment to high standards of clinical excellence and ethical research practices, Qilu Hospital plays a pivotal role in enhancing patient outcomes and contributing to the global medical community through a diverse range of clinical trials and studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Patients applied
Trial Officials
Yonghui Wang, professor
Principal Investigator
Qilu Hospital of Shandong University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported